Skip to content

Internet-based MOTOmed Exercise to Reduce Spasticity and Improve Physical Function in Persons With Multiple Sclerosis

Internet-based Physical Activity Promotion Using the MOTOmed Movement Trainer to Reduce Spasticity and Improve Physical Function in Moderately to Severely Affected Persons With Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03548974
Enrollment
57
Registered
2018-06-07
Start date
2015-01-31
Completion date
2015-10-31
Last updated
2018-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Spasticity, MOTOmed training, internet

Brief summary

In an RCT, the effect of the MOTOmed movement trainer (Reck, Germany) on spasticity and physical function in pwMS with EDSS score between 4,5 and 7 is investigated. All subjects exercise at home and are supervised and supported by an exercise therapist via an online platform. We compare the effect of a 12 week passive, motor-driven movement therapy (VG1) to an intermittent active and passive training (VG2). After 12 weeks, VG1 continues with an active training including strengthening exercises for another 12 weeks. VG2 does not receive any intervention in the second study phase.

Interventions

The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.

BEHAVIORALTreatment group 2

The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)

Sponsors

Fa. Reck MOTOmed
CollaboratorUNKNOWN
University of Erlangen-Nürnberg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

diagnosed Multiple Sclerosis (McDonald criteria) EDSS score between 5,5 and 7 diagnosed spasticity access to the internet

Exclusion criteria

lack of medical certificate for physical activity cognitive impairment clinically relevant internal disease, especially cardiovascular or pulmonary disease, metabolic and orthopedic diseases

Design outcomes

Primary

MeasureTime frameDescription
Change in spasticity: MSSS-88Assessments took place at baseline, at 3 and 6 monthsThis questionnaire contains 88 items, which represent the impairment by the spasticity in various subscales. The total score ranges from 88 to a maximum of 352 points (maximum impairment).
Change in sSpasticity: Modified Tardieu scaleAssessments took place at baseline, at 3 and 6 monthsThe scale is measuring spasticity as response to passive movement at both slow and fast speed; scored 0 - 4. (0=no resistance; 4= inexhaustible clonus)

Secondary

MeasureTime frameDescription
Change in function: 5-Chair-RiseAssessments took place at baseline, at 3 and 6 monthsThe main task in this test is to get up and sit down 5 times as fast as possible without use of the arms. The goal is the global assessment of the strength of the lower limb.
Change in function: 25foot-walk-testAssessments took place at baseline, at 3 and 6 monthsThe task is to walk a 25foot distance as fast as possible. This test measures the functionality of the lower extremity and the walking speed.
Change in function: 2min-walkAssessments took place at baseline, at 3 and 6 monthsThe subject is asked to walk with the fastest, possible speed to cover the greatest possible distance in 2min.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026